| [1] |
Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
doi: 10.3322/caac.21338
|
| [2] |
Li K, Yang M, Liang N , et al. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: perplexity and solution (review)[J]. Oncol Rep, 2017,37(3):1347-1358. DOI: 10.3892/or.2017.5409.
doi: 10.3892/or.2017.5409
|
| [3] |
Kohno T, Nakaoku T, Tsuta K , et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer[J]. Transl Lung Cancer Res, 2015,4(2):156-164. DOI: 10.3978/j.issn.2218-6751.2014.11.11.
|
| [4] |
Han B, Tjulandin S, Hagiwara K , et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study[J]. Lung Cancer, 2017,113:37-44. DOI: 10.1016/j.lungcan.2017.08.021.
doi: 10.1016/j.lungcan.2017.08.021
|
| [5] |
Beau-Faller M, Prim N, Ruppert AM , et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network[J]. Ann Oncol, 2014,25(1):126-131. DOI: 10.1093/annonc/mdt418.
doi: 10.1093/annonc/mdt418
|
| [6] |
Gahr S, Stoehr R, Geissinger E , et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice[J]. Br J Cancer, 2013,109(7):1821-1828. DOI: 10.1038/bjc.2013.511.
doi: 10.1038/bjc.2013.511
|
| [7] |
Shi Y, Au JS, Thongprasert S , et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014,9(2):154-162. DOI: 10.1097/JTO.0000000000000033.
doi: 10.1097/JTO.0000000000000033
|
| [8] |
Yang TY, Tsai CR, Chen KC , et al. Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene[J]. J Clin Oncol, 2011,29(16):e468-e469. DOI: 10.1200/JCO.2010.33.5802.
doi: 10.1200/JCO.2010.33.5802
|
| [9] |
Gazdar AF, Shigematsu H, Herz J , et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?[J]. Trends Mol Med, 2004,10(10):481-486. DOI: 10.1016/j.molmed.2004.08.008.
doi: 10.1016/j.molmed.2004.08.008
|
| [10] |
Zhao Q, Shentu J, Xu N , et al. Phase Ⅰ study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors[J]. Lung Cancer, 2011,73(2):195-202. DOI: 10.1016/j.lungcan.2010.11.007.
doi: 10.1016/j.lungcan.2010.11.007
|
| [11] |
Canale M, Petracci E, Delmonte A , et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors[J]. Clin Cancer Res, 2017,23(9):2195-2202. DOI: 10.1158/1078-0432.CCR-16-0966.
doi: 10.1158/1078-0432.CCR-16-0966
|
| [12] |
Yang JC, Sequist LV, Geater SL , et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015,16(7):830-838. DOI: 10.1016/S1470-2045(15)00026-1.
doi: 10.1016/S1470-2045(15)00026-1
|
| [13] |
刘志艳, 王佩国, 王平 , 等. 表皮生长因子受体靶向治疗非小细胞肺癌[J]. 国际肿瘤学杂志, 2006,33(3):205-207. DOI: 10.3760/cma.j.issn.1673-422X.2006.03.016.
|
